Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.
In the latest session, Regenxbio Inc (NASDAQ: RGNX) closed at $16.06 up 0.12% from its previous closing price of $16.04. In other words, the price has increased by $0.12 from its previous closing price. On the day, 0.6 million shares were traded. RGNX stock price reached its highest trading level at $16.16 during the session, while it also had its lowest trading level at $15.29.
Ratios:
For a deeper understanding of Regenxbio Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.57 and its Current Ratio is at 2.57. In the meantime, Its Debt-to-Equity ratio is 0.29 whereas as Long-Term Debt/Eq ratio is at 0.26.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, H.C. Wainwright on March 11, 2024, initiated with a Buy rating and assigned the stock a target price of $36.
On March 08, 2024, RBC Capital Mkts Upgraded its rating to Outperform which previously was Sector Perform and also upped its target price recommendation from $20 to $35.
Leerink Partners Upgraded its Market Perform to Outperform on March 06, 2024, while the target price for the stock was maintained at $37.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Apr 15 ’24 when Mills Kenneth T. sold 15,000 shares for $18.19 per share. The transaction valued at 272,871 led to the insider holds 408,035 shares of the business.
Mills Kenneth T. sold 15,000 shares of RGNX for $327,942 on Mar 14 ’24. The President and CEO now owns 408,035 shares after completing the transaction at $21.86 per share. On Mar 05 ’24, another insider, PAKOLA STEVE, who serves as the Chief Medical Officer of the company, sold 12,878 shares for $28.36 each. As a result, the insider received 365,220 and left with 107,192 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RGNX now has a Market Capitalization of 787625728 and an Enterprise Value of 621590528. For the stock, the TTM Price-to-Sale (P/S) ratio is 8.72 while its Price-to-Book (P/B) ratio in mrq is 2.27. Its current Enterprise Value per Revenue stands at 6.888 whereas that against EBITDA is -2.515.
Stock Price History:
Over the past 52 weeks, RGNX has reached a high of $28.80, while it has fallen to a 52-week low of $11.83. The 50-Day Moving Average of the stock is -19.00%, while the 200-Day Moving Average is calculated to be -9.91%.
Shares Statistics:
For the past three months, RGNX has traded an average of 742.22K shares per day and 456080 over the past ten days. A total of 48.99M shares are outstanding, with a floating share count of 44.38M. Insiders hold about 9.41% of the company’s shares, while institutions hold 79.48% stake in the company. Shares short for RGNX as of 1713139200 were 4065835 with a Short Ratio of 5.48, compared to 1710460800 on 4150440. Therefore, it implies a Short% of Shares Outstanding of 4065835 and a Short% of Float of 10.870000000000001.
